IBDEI2M0 ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,869,0)
 ;;=RADIOEMOBOLIZATION PRE/MAPPING^7^77
 ;;^UTILITY(U,$J,358.4,870,0)
 ;;=RADIATION DELIVERY/TREATMENT PLANNING^8^77
 ;;^UTILITY(U,$J,358.4,871,0)
 ;;=NEW PATIENT^2^78
 ;;^UTILITY(U,$J,358.4,872,0)
 ;;=ESTABLISHED PATIENT^1^78
 ;;^UTILITY(U,$J,358.4,873,0)
 ;;=CONSULTATIONS^3^78
 ;;^UTILITY(U,$J,358.4,874,0)
 ;;=COMMON VASCULAR DX^1^79
 ;;^UTILITY(U,$J,358.4,875,0)
 ;;=ABDOMINAL PAIN^2^79
 ;;^UTILITY(U,$J,358.4,876,0)
 ;;=AFTERCARE POST SURGERY^3^79
 ;;^UTILITY(U,$J,358.4,877,0)
 ;;=CARDIOVASCULAR^4^79
 ;;^UTILITY(U,$J,358.4,878,0)
 ;;=GENERAL/SIGNS/SYMPTOMS^5^79
 ;;^UTILITY(U,$J,358.4,879,0)
 ;;=HEMATOLOGY/ONCOLOGY^6^79
 ;;^UTILITY(U,$J,358.4,880,0)
 ;;=INFECTIOUS DISEASE^7^79
 ;;^UTILITY(U,$J,358.4,881,0)
 ;;=METASTATIC CANCER SITES^8^79
 ;;^UTILITY(U,$J,358.4,882,0)
 ;;=POST-OP COMPLICATIONS^9^79
 ;;^UTILITY(U,$J,358.4,883,0)
 ;;=RESPIRATORY^10^79
 ;;^UTILITY(U,$J,358.4,884,0)
 ;;=BLIND REHAB SERVICE CODES^2^80
 ;;^UTILITY(U,$J,358.4,885,0)
 ;;=REFRACTION^6^80
 ;;^UTILITY(U,$J,358.4,886,0)
 ;;=GLASSES/CONTACT LENSES^3^80
 ;;^UTILITY(U,$J,358.4,887,0)
 ;;=VISUAL FIELDS^9^80
 ;;^UTILITY(U,$J,358.4,888,0)
 ;;=PHOTOGRAPHY^5^80
 ;;^UTILITY(U,$J,358.4,889,0)
 ;;=LOW VISION^4^80
 ;;^UTILITY(U,$J,358.4,890,0)
 ;;=SPECIAL PROCEDURES^7^80
 ;;^UTILITY(U,$J,358.4,891,0)
 ;;=TEAM MEETINGS/COUNSELING^8^80
 ;;^UTILITY(U,$J,358.4,892,0)
 ;;=ASSESSMENT/COUNSELING^1^80
 ;;^UTILITY(U,$J,358.4,893,0)
 ;;=ESTABLISHED PATIENT^1^81
 ;;^UTILITY(U,$J,358.4,894,0)
 ;;=NEW PATIENT^2^81
 ;;^UTILITY(U,$J,358.4,895,0)
 ;;=CONSULTATION^3^81
 ;;^UTILITY(U,$J,358.4,896,0)
 ;;=PROLONGED SERVICE^4^81
 ;;^UTILITY(U,$J,358.4,897,0)
 ;;=CONJUNCTIVA/CORNEA^2^82
 ;;^UTILITY(U,$J,358.4,898,0)
 ;;=DIABETES^3^82
 ;;^UTILITY(U,$J,358.4,899,0)
 ;;=GLAUCOMA^4^82
 ;;^UTILITY(U,$J,358.4,900,0)
 ;;=LENS/VITREOUS^5^82
 ;;^UTILITY(U,$J,358.4,901,0)
 ;;=LIDS/LASHES^6^82
 ;;^UTILITY(U,$J,358.4,902,0)
 ;;=MACULA/OPTIC NERVE^7^82
 ;;^UTILITY(U,$J,358.4,903,0)
 ;;=PUPILS/IRIS^8^82
 ;;^UTILITY(U,$J,358.4,904,0)
 ;;=RETINA^9^82
 ;;^UTILITY(U,$J,358.4,905,0)
 ;;=VF HA EOM OTHER^10^82
 ;;^UTILITY(U,$J,358.4,906,0)
 ;;=VA VF^1^82
 ;;^UTILITY(U,$J,358.4,907,0)
 ;;=MFH-NON CLINICIAN VISIT ^2^83
 ;;^UTILITY(U,$J,358.4,908,0)
 ;;=NURSING PROCEDURES^3^83
 ;;^UTILITY(U,$J,358.4,909,0)
 ;;=SPLINTS^4^83
 ;;^UTILITY(U,$J,358.4,910,0)
 ;;=MFH-CLINICIAN VISIT ^1^83
 ;;^UTILITY(U,$J,358.4,911,0)
 ;;=VACCINE ADMINISTRATION^5^83
 ;;^UTILITY(U,$J,358.4,912,0)
 ;;=VACCINES^6^83
 ;;^UTILITY(U,$J,358.4,913,0)
 ;;=PC COMMON DIAGNOSES^1^84
 ;;^UTILITY(U,$J,358.4,914,0)
 ;;=ADMINISTRATIVE TOPICS^2^84
 ;;^UTILITY(U,$J,358.4,915,0)
 ;;=ANGINA^3^84
 ;;^UTILITY(U,$J,358.4,916,0)
 ;;=ATHEROSCLEROSIS^4^84
 ;;^UTILITY(U,$J,358.4,917,0)
 ;;=CARDIOVASCULAR^5^84
 ;;^UTILITY(U,$J,358.4,918,0)
 ;;=DERMATOLOGY^9^84
 ;;^UTILITY(U,$J,358.4,919,0)
 ;;=EAR DISORDERS^10^84
 ;;^UTILITY(U,$J,358.4,920,0)
 ;;=EENT^11^84
 ;;^UTILITY(U,$J,358.4,921,0)
 ;;=ENDOCRINE/METABOLIC^12^84
 ;;^UTILITY(U,$J,358.4,922,0)
 ;;=EYE DISORDERS^13^84
 ;;^UTILITY(U,$J,358.4,923,0)
 ;;=EYE INJURY^14^84
 ;;^UTILITY(U,$J,358.4,924,0)
 ;;=GASTROENTEROLOGY^15^84
 ;;^UTILITY(U,$J,358.4,925,0)
 ;;=GU/RENAL^16^84
 ;;^UTILITY(U,$J,358.4,926,0)
 ;;=HEADACHE^17^84
 ;;^UTILITY(U,$J,358.4,927,0)
 ;;=HEART FAILURE^18^84
 ;;^UTILITY(U,$J,358.4,928,0)
 ;;=HEART VALVE DISEASE^19^84
 ;;^UTILITY(U,$J,358.4,929,0)
 ;;=HEMATOLOGY/ONCOLOGY^20^84
 ;;^UTILITY(U,$J,358.4,930,0)
 ;;=HISTORY OF ILLNESS^21^84
 ;;^UTILITY(U,$J,358.4,931,0)
 ;;=INFECTIOUS DISEASE^22^84
 ;;^UTILITY(U,$J,358.4,932,0)
 ;;=LIVER DISEASE^23^84
